Patricia A. Martin
Known title: DirectorCIK: 0001916764
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.
Transaction History
| CYPH | ▼ Sell | Open Market | 50,000 | $193K | 9/23/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 766 | $0 | 7/10/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 1,192 | $0 | 4/10/2026 | View on chart |
| CYPH | ▲ Buy | Option Exercise | 74,700 | — | 3/13/2026 | View on chart |
| CYPH | ▲ Buy | Option Exercise | 94,050 | — | 3/13/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 3,650 | $0 | 1/12/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 3,274 | $0 | 10/10/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 3,750 | $0 | 7/10/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 3,065 | $0 | 4/10/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 3,166 | $0 | 12/19/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CYPH in Spotlight as Smaller Health Care Names Outperform
Recent coverage noted that smaller health‑care names outperformed larger peers, and CYPH is among those that could benefit from the sector’s momentum. The same report highlighted significant whale activity in health‑care stocks, suggesting growing institutional interest. These developments may affect CYPH’s trading dynamics. No specific price guidance is provided.
CYPH in Spotlight as Smaller Health Care Names Outperform. Recent coverage noted that smaller health‑care names outperformed larger peers, and CYPH is among those that could benefit from the sector’s momentum. The same report highlighted significant whale activity in health‑care stocks, suggesting growing institutional interest. These developments may affect CYPH’s trading dynamics. No specific price guidance is provided.